首页> 外文OA文献 >Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
【2h】

Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.

机译:CD8 +或CD4 +次要组织相容性抗原特异性细胞毒性T淋巴细胞对克隆性白血病细胞,缓解性骨髓和HLA相同供体骨髓的识别。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We investigated whether minor histocompatibility (mH) antigen-specific cytotoxic T lymphocytes (CTL) can discriminate between leukemic hematopoietic progenitor cells (leukemic-HPC) from AML or CML patients, the HPC from their remission bone marrow (remission-HPC), and normal HPC from their HLA-identical sibling bone marrow donor (donor-HPC). Specific lysis by CD8+ CTL clones was observed not only of the leukemic-HPC but also of the donor-HPC in 3/4 patient/donor combinations expressing mH antigen HA-1, 3/5 combinations expressing mH antigen HA-2, 2/3 combinations expressing mH antigen HA-3, and 2/2 combinations expressing mH antigen HY-A1. In four patient/donor combinations the recognition of the donor-HPC was clearly less than of the leukemic-HPC, indicating differential susceptibility to lysis by these mH CTL clones. In addition, differential recognition of leukemic-HPC and remission-HPC within seven patients was analyzed. In one patient expressing the HA-2 antigen on the leukemic cells the recognition of the remission-HPC was clearly less than of the leukemic-HPC. One CD4+ CTL clone showed specific lysis of the leukemic-HPC from an AML patient and a CML patient as well as of normal remission-HPC and donor-HPC. These results illustrate that in general CD8+ and CD4+ mH antigen specific CTL clones do not differentially recognize leukemic-HPC and normal-HPC. However, differences in susceptibility to lysis of malignant versus normal cells may contribute to a differential GVL effect.
机译:我们调查了是否存在较小的组织相容性(mH)抗原特异性细胞毒性T淋巴细胞(CTL)可以区分AML或CML患者的白血病造血祖细胞(leukmic-HPC),其缓解骨髓的HPC(remission-HPC)和正常来自其HLA相同的同胞骨髓供体(donor-HPC)的HPC。在表达mH抗原HA-1的3/4患者/供体组合,表达mH抗原HA-2、2 / 3的3/5组合中,不仅观察到了白血病HPC,而且观察到了供体HPC的CD8 + CTL克隆特异性裂解。表达mH抗原HA-3的3种组合和表达mH抗原HY-A1的2/2组合。在四种患者/供体组合中,供体-HPC的识别率明显低于白血病-HPC,表明这些mH CTL克隆对裂解的敏感性不同。此外,分析了七名患者中白血病HPC和缓解HPC的差异识别。在一名在白血病细胞上表达HA-2抗原的患者中,缓解HPC的识别率明显低于白血病HPC。一个CD4 + CTL克隆显示了来自AML患者和CML患者的白血病HPC的特异性裂解,以及正常缓解HPC和供体HPC的特异性裂解。这些结果说明,一般而言,CD8 +和CD4 + mH抗原特异性CTL克隆不能差异性识别白血病HPC和正常HPC。但是,恶性细胞与正常细胞相比,其溶解敏感性不同可能会导致GVL差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号